North China Pharmaceutical Group, the predecessor of the North China Pharmaceutical Plant is China's "First Five-Year Plan" during the key construction projects. First Five-Year Plan nationwide **** arranged 694 large and medium-sized construction projects, the pharmaceutical industry in all the projects accounted for four: antibiotics factory, starch factory, glass factory and sulfonamide factory. Among the four projects, North China Pharmaceutical Plant accounted for three of them, i.e. antibiotic plant introduced from the Soviet Union, starch plant and pharmaceutical glass plant introduced from the German Democratic **** and the country. 1953 June, North China Pharmaceutical Plant began preparations for the three projects in 1955-1956 years, groundbreaking, and in 1958 all completed and put into operation. With a total investment of 75.88 million RMB, North China Pharmaceutical Factory covers an area of 247,000 square meters, with a total construction area of 106,000 square meters, and is designed to have an annual output of 32.5 tons of penicillin, 53 tons of streptomycin, 14,850 tons of dry starch, 1,712 tons of dextrose, and 290 million vials of medicinal glass. North China Pharmaceutical Plant was put into operation to end the history of China's dependence on imports of penicillin and streptomycin, and has become an important base for the production of antibiotics and the export of talents in the new China.
The development course of NCPP can be roughly divided into three stages:
1. The first stage is from 1958 to 1978, North China Pharmaceutical Factory relied on digging the connotation of development, through pioneering and innovating, digesting the imported technology, and grasping the selection of bacterial strains and reforming and optimizing the conditions of the fermentation and refining process, so as to make the level of antibiotic production step into the ranks of the international advanced at that time. The number of products increased from 5 at the time of plant construction to 75, and the total annual output of antibiotics increased by nearly 20 times, initially laying down the advantages of scale and cost. Relying on its own strength, North China Pharmaceutical Factory in 1958, 1959, built hygromycin, propylene solvent workshop, built from streptomycin waste liquid extraction of vitamin B12 section. 1969 in hygromycin plant built tetracycline section. 1970, May, the glass factory vials workshop trial production of tubes successfully, in February 1975, set up the North China Pharmaceutical Factory tubes sub-factory in 1981 to the Provincial Bureau of Electronics, became the Shijiazhuang City tubes. In 1981, it was transferred to the provincial electronics bureau, and became Shijiazhuang city picture tube factory (that is, later Shijiazhuang gem electronic group company). 1973 started construction of anti-cancer drug synthesis workshop, completed in 1979, changed to the production of lincomycin. 1970, North China Pharmaceutical Factory, the center of the laboratory was reorganized into the antibiotic research institute. In 1970, the central laboratory of North China Pharmaceutical Factory was reorganized into the Institute of Antibiotics. The new antibiotics developed by the Institute of Antibiotics over the years include: bacillus peptide, desmethyl vancomycin, neomycin, triclosporin, chlortetracycline, erythromycin, streptomycin, lincomycin, lincomycin, lushanamycin, pingyangamycin, clindamycin hydrochloride, and cephalosporin C.
2, the second stage of the development of Chinese medicine is 1979 to 1990, the focus of this stage is the transformation of the enterprise, the implementation of business contracting, the implementation of modern management, horizontal integration and technology transfer, and gradually strengthen the introduction of advanced technology and equipment. The total number of product varieties increased to 98, and the total output of antibiotics increased by 54% compared with that of 1978. 1981, North China Pharmaceutical Factory set up the Total Quality Management Office (changed to the Enterprise Management Office in 1983), introduced and popularized the total quality management, and the quality of the enterprise was improved continuously. 1986 won the National Quality Management Prize, and was upgraded to the National Second Grade Enterprise in 1987, and to the National First Grade Enterprise in 1989. National Level Enterprise in 1989. Among the 26 main products of North China brand, 2 of them have been honored with Ministry of Chemical Industry, 8 of them have been honored with State Pharmaceutical Administration Bureau of Excellence, and 23 of them have been honored with Provincial Quality Products (including 7 Bureau of Excellence products). Five main products have been awarded three gold and silver medals each of the National Quality Award. Since 1981, Huayao has gradually carried out cross-regional and cross-industry horizontal economic alliances, and by the end of 1990, there were 25 closely-knit joint ventures. The cumulative investment in the 25 closely-associated enterprises amounted to 53.6 million yuan.
In December 1982, North China Pharmaceutical Factory completed the second penicillin production line, doubling the production capacity of penicillin.
3. Since 1991, Huayu entered the third stage of development. During this period, Huayu actively adapted to the new situation of market economy, deepened the enterprise reform, transformed the business mechanism, increased the technical reform, infrastructure, and strengthened the scale of the enterprise through external attraction and internal association, and the production and operation and all undertakings have achieved great development. By 1997, the total industrial output value, sales revenue and profit tax of Huayu Pharmaceutical had increased by 326%, 422% and 161% respectively compared with that of 1991, and the cumulative number of products had increased to more than 300 kinds of products.North China Pharmaceutical Group was established on March 10, 1991, and then listed as one of the first 55 pilot groups by the State Council, and it obtained the right of import and export of foreign trade and the right of approving foreign affairs, and successively set up the financial company and the new drug research and development center. In October 1992, North China Pharmaceutical Factory carried out shareholding reform for the production and operation part, and formed North China Pharmaceutical Company Limited after directional fund-raising. 1993, North China Pharmaceutical Company Limited raised shares to the public, and in 1994, Huayu Pharmaceutical Company Limited was listed on the Stock Exchange of China, and became one of the first listed companies in Hebei Province. 1995 and 1997, Huayu Pharmaceutical Company Limited increased its capital and allotted shares twice, and the shares of Huayu Pharmaceutical Company Limited increased its capital and allotted shares twice, and Huayu Pharmaceutical Company Limited increased its shares twice. In 1995 and 1997, Sinopharm was listed on the Shanghai Stock Exchange and became one of the first listed companies in Hebei Province. Through directional fund-raising, social fund-raising and two capital increase and share allocation, Huayao raised 700 million yuan of social capital. These funds were all used for Huayu's technological reform, infrastructure and new product development projects during the 8th and 9th Five-Year Plan periods, so that these projects maintained a high speed, high quality and high level. 1992, Huayu began to utilize foreign capital. Within six years, it has created sixteen Sino-foreign joint ventures and cooperative companies, completed one compensation trade project, and utilized a total of 70 million US dollars of foreign capital. According to the needs of enterprise development strategy, Huayu implemented asset reorganization, has acquired, merged 12 enterprises, leasing operation of two enterprises, expanding the scale and strength.In January 1996, the North China Pharmaceutical Factory was reorganized into a wholly state-owned company ---- North China Pharmaceutical Group Limited Liability Company.